Vistagen to present at the 2025 anxiety and depression association conference

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the anxiety and depression association of america (adaa) conference in las vegas, nevada from april 3 to 5, 2025. the company's poster presentations will explore the age of onset of social anxiety diso.
VTGN Ratings Summary
VTGN Quant Ranking